AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board
News Feb 09, 2012
Mr. De Silva is currently president of Valeant Pharmaceuticals International, Inc. and chief operating officer of its Specialty Pharmaceuticals business. Mr. Santini retired in 2010 from a 27-year career at Eli Lilly and Company, where he held a variety of commercial and operational roles, serving most recently as senior vice president, corporate strategy and business development.
“As we continue to evaluate strategic alternatives for AMAG, the perspective that Rajiv and Gino bring to the table will be invaluable to AMAG and our board,” said Michael Narachi, chairman of AMAG’s board of directors. “Rajiv’s operations experience at Valeant and Novartis, coupled with Gino’s long history as a successful commercial leader and experience defining and executing corporate strategy at Lilly will support the key decisions facing the board in the coming months. Their expertise will be valuable assets to the board as we explore a sale of the company and simultaneously establish a solid foundation from which to drive growth and profitability if AMAG remains an independent company. ”
Mr. De Silva, age 45, joined Valeant in January 2009. He was named Valeant’s president in October 2010 and is responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. From 2003 to 2009, Mr. De Silva held various leadership positions of increasing responsibility at Novartis AG, most recently as president, Novartis Vaccines USA and head, vaccines of the Americas. Prior to his time at Novartis, Mr. De Silva was a partner at McKinsey & Company, a management consulting firm, where he focused his consulting practice on the pharmaceutical industry. Mr. De Silva holds a Bachelor of Science in Engineering from Princeton University, a Master of Science from Stanford University, and a Master of Business Administration from the Wharton School at the University of Pennsylvania.
Mr. Santini, age 55, had a distinguished career with Eli Lilly that spanned nearly three decades. During his tenure at Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, president of the women’s health franchise and president of U.S. operations. Mr. Santini capped his career at Lilly as a member of the company’s executive committee and as the senior vice president of corporate strategy and business development. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master’s in business administration from the University of Rochester.